Epidermal growth factor stimulates Rac1 and p21-activated kinase in vascular smooth muscle cells

被引:24
作者
Beier, Imke [1 ]
Duesing, Rainer [1 ]
Vetter, Hans [1 ]
Schmitz, Udo [1 ]
机构
[1] Med Univ Poliklin, D-53111 Bonn, Germany
关键词
epidermal growth factor; vascular smooth muscle cells; Rho-family G-proteins; Rac; Cdc42; P21-activated kinase; Jnk;
D O I
10.1016/j.atherosclerosis.2007.02.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epidermal growth factor (EGF) has been shown to be a potent mitogen for vascular smooth muscle cells (VSMC) both in vitro and in vivo, thus contributing to the development of atherosclerosis and hypertension. Stimulation of Rho-family GTPases Rac/Cdc42 exerts pleiotropic cellular effects and have been demonstrated to contribute to EGF-induced proliferation in other cell systems. However, the effect of EGF on Rac/Cdc42 activation is unknown for VSMC. In the present report, we evaluated stimulation of Rac/Cdc42 by EGF in VSMC performing PAK-PBD binding assay. EGF treatment of VSMC induced time and concentration dependent binding of GTP-bound Rac1 to PAK-PBD peaking at 1 min and showing sustained activation up to 15 min. However, stimulation of Cdc42 could not be demonstrated. To further evaluate downstream effectors of Rac1 stimulation of p21-activated kinase (PAK) and c-Jun N-terminal kinase (JNK) by EGF was determined. In VSMC, EGF sequentially stimulated PAK, peaking at 5 min, and JNK, peaking at 15 min. Pretreatment of VSMC by EGF receptor specific tyrosine kinase inhibitor AG1478 and non-specific tyrosine kinase inhibitor genistem inhibited EGF-induced activation of Rac1, PAK and JNK, whereas tyrosine kinase inhibitors specific for Src (PP1) and specific for platelet-derived growth factor (AG1296) had no effect. Specific inhibition or Rac1 by NSC23766 attenuated EGF-induced [H-3] thymidine incorporation in VSMC. Our data provide evidence for EGF-induced Rac1 activation and implicate PAK and JNK as downstream targets of Rac1 in EGF signal transduction in VSMC. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 23 条
[1]   Identification of a mouse p21(cdc42/Rac) activated kinase (vol 270, pg 22731, 1995) [J].
Bagrodia, S ;
Taylor, SJ ;
Creasy, CL ;
Chernoff, J ;
Cerione, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) :1250-1250
[2]   Characterization of Rac and Cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases [J].
Benard, V ;
Bohl, BP ;
Bokoch, GM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13198-13204
[3]   Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor [J].
Bokemeyer, D ;
Schmitz, U ;
Kramer, HJ .
KIDNEY INTERNATIONAL, 2000, 58 (02) :549-558
[4]  
Doanes AM, 1998, BIOCHEM MOL BIOL INT, V45, P279
[5]   ANGIOTENSIN-II STIMULATES THE PP44 AND PP42 MITOGEN-ACTIVATED PROTEIN-KINASES IN CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS [J].
DUFF, JL ;
BERK, BC ;
CORSON, MA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 188 (01) :257-264
[6]   Fibroblast growth factor-2 and remodeled type I collagen control membrane protrusion in human vascular smooth muscle cells - Biphasic activation of Rac1 [J].
Fera, E ;
O'Neil, C ;
Lee, W ;
Li, SH ;
Pickering, JG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (34) :35573-35582
[7]   Rho GTPases and the actin cytoskeleton [J].
Hall, A .
SCIENCE, 1998, 279 (5350) :509-514
[8]   Expression of heparin-binding epidermal growth factor-like growth factor in neointimal cells induced by balloon injury in rat carotid arteries [J].
Igura, T ;
Kawata, S ;
Miyagawa, J ;
Inui, Y ;
Tamura, S ;
Fukuda, K ;
Isozaki, K ;
Yamamori, K ;
Taniguchi, N ;
Higashiyama, S ;
Matsuzawa, Y .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (12) :1524-1531
[9]   Coactivation of Rad1 and Cdc42 at lamellipodia and membrane ruffles induced by epidermal growth factor [J].
Kurokawa, K ;
Itoh, RE ;
Yoshizaki, H ;
Ohba, Y ;
Nakamura, T ;
Matsuda, M .
MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (03) :1003-1010
[10]  
Major TC, 1997, J PHARMACOL EXP THER, V283, P402